RxDoctor Payments Data

Emily Baertsch

Family · Rapid City, SDNPI 1225669211

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 30.5% of the total. Among family clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,542in general payments, 2019–2025

Across 76 payments — averaging $33.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$775
  • Takeda Pharmaceuticals U.S.A., Inc.$538
  • Madrigal Pharmaceuticals$316
  • Johnson & Johnson$241
  • Sirtex Medical Inc$132
  • Ardelyx, Inc.$125
  • plus $416 from 6 others

What the payments were for

  • Food & beverage$2,45396%
  • Education$894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,542 in reported general payments places this provider in the 90th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$78,621
Medicare patients
353
Services billed
1,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid18$225,896
XifaxanRifaximin33$125,922
CreonLipase/Protease/Amylase27$60,340
LinzessLinaclotide26$23,002
Ursodiol113$20,448
Dexlansoprazole DrDexlansoprazole27$7,499
Sucralfate43$3,710
Mesalamine19$3,513
Esomeprazole Magnesium64$2,886
Omeprazole176$1,509
Azathioprine33$1,299
Colestipol Hcl18$1,193
Pantoprazole Sodium107$1,107
Famotidine118$995
Dicyclomine Hcl52$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$29$225,89618 claims
AbbVieCreon, Linzess$775$83,34253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family providers in South Dakota.

Other family in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →